Report Overview

The global liver cancer therapeutics market was pegged at US$ 1.8 billion in 2021 and is expected to register a revenue CAGR of 19.5% during the forecast period.

Market Fundamentals 

Liver cancer is a type of malignant hepatic tumor that develops in or on the liver. Liver cancer can be caused because of underlying diseases such as hepatitis, diabetes, some genetic liver illnesses, and excessive alcohol consumption. Symptoms of liver cancer appear only after the cancer has grown. The most common kind of liver cancer is hepatocellular carcinoma, which begins in the primary type of liver cell.

[345234234]

Market Dynamic

The global market for liver cancer therapeutics is expected to register rapid revenue growth during the forecast period because of the rise in research activities to determine the causes of liver cancer. Furthermore, the market revenue is expected to grow because of the rising prevalence of liver cancer. During the forecast period, the liver cancer treatment market revenue growth is expected to be driven by the increased prevalence of metastatic cancer that spreads from other regions of the body, such as breast cancer, colon cancer, or lung cancer. 

The market revenue of liver cancer therapies will expand because of the emergence of innovative therapeutic drugs, a strong clinical pipeline of therapeutics, increased global awareness, and supportive government policies.

However, factors such as strict regulatory clearances to assure the safety of pharmaceuticals and the cost of these drugs are expected to hamper the revenue growth of the liver cancer therapeutics market to some extent.

Market Ecosystem

The global liver cancer therapeutics market has been analyzed from three perspectives: therapy type, distribution channel, and region. 

Liver Cancer Therapeutics Market by Therapy Type

[8645433]

Based on the therapy type, the global liver cancer therapeutics market has been segmented into chemotherapy, immunotherapy, and targeted therapy. 

The targeted therapy segment is expected to dominate the global liver cancer therapeutics market in terms of revenue during the forecast period. The targeted therapy is administered intravenously through blood and these drugs spread across the body and help kill cancer cells that are present in other parts of the body. The targeted therapy most commonly comprises the use of tyrosine kinase inhibitors which inhibit the several kinase proteins that stimulate cancer cell growth.

Liver Cancer Therapeutics Market by Distribution Channel

Based on the distribution channel, the global liver cancer therapeutics market is segmented into retail pharmacy, online pharmacy, and hospital pharmacy. 

The hospital pharmacy segment is expected to be the leading distribution channel in the global market during the forecast period. This is due to the high sales of prescribed medication and patient footfall in the hospital.

Liver cancer therapeutics Market by Region 

Based on region, the global liver cancer therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. 

During the forecast period, North America is expected to lead the global liver cancer therapeutics market in terms of revenue. The high revenue share of North America in the global market is attributed to the high prevalence of liver cancer, early detection of liver cancer, accessibility of cancer therapeutic drugs, high levels of awareness about liver cancer, and a well-established healthcare infrastructure in the region. Additionally, the region's early adoption of cutting-edge diagnostic tools and methods for the treatment of liver cancer and the presence of major pharmaceutical and biotechnology firms in the region are expected to drive market revenue growth in the region.

Competitive Landscape

 The prominent players operating in the global liver cancer therapeutics market are: 

• Pfizer Inc.
• Bristol-Myerrs & Squibb Company
• Exelixis Inc.
• Merck Sharp & Dohme Corp.
• Eli Lilly & Company
• F. Hoffman-La Roche Ltd.
• Eisai Co., Ltd.
• Celgene Corporation
• Amgen Inc.
• Onyx Pharmaceuticals, Inc.

Strategic Developments

• In September 2022, Novartis announced the efficacy and tolerability of the drug tislelizumab which was demonstrated in first-line advanced liver cancer in a Phase III trial.
• In September 2022, AstraZeneca’s drug Imfinzi was approved by the U.S. FDA that would be used for the treatment of patients with metastatic biliary tract cancer in combination with chemotherapy.

Frequently Asked Questions About This Report